Loading clinical trials...
Loading clinical trials...
The purpose of this study is to explore the Efficacy and Safety of DWP450 for treating Crows Feet Lines(CFL) in combination with glabellar line(GL) as extension study of phase 3 study for CFL.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Daewoong Pharmaceutical Co. LTD.
NCT07435428 · Moderate to Severe Glabellar Lines
NCT06481475 · Moderate to Severe Glabellar Lines
NCT06205797 · Glabellar Lines
NCT07321834 · Glabellar Lines
NCT06583486 · Moderate to Severe Glabellar Lines
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions